However, after treatment with AR pathway inhibitors such as ENZ and ABI, these luminal cells transdifferentiate to form neuroendocrine cells leading to therapy-induced PCa (NEPC), an aggressive subtype of CRPC characterized by low PSA and no AR signaling[26-30]. Here, PROS1 is linked to posterior cortical atrophy.